HungaryHungary

MON810 GM-Maize Banned

05.02.2005

Budapest - The Hungarian Ministry of Agriculture and Regional Development has banned the creation, use, distribution and import of seeds from inbred lines or hybrids of the transgenic MON810 maize line in January. The ban also applies to plants derived from crossbreeding with traditionally cultivated maize. However, this does not cover the use of varieties in the food and feed industry, their repackaging or transfer without further treatment if it can be ensured that the maize will not be liberated into the environment.
According to the Hungarian daily Népszabadság the country is the first among the European Union's (EU) new member states to bring about such a decision. The European Commission added 17 MON810 maize varieties to the EU's sort list last September, paving the way for their distribution in the Member States apart from those which exercized a hedge clause like Austria. The Ministry will not allow the use of any genetically modified (GM) plants until preconditions of their cultivation, handling and distribution have been regulated in detail in a co-existence law. Ministry spokesperson András Dékány told the Hungarian online service Origo that the drafting of this law could start this autumn. He explained that the ban aims at protecting autochthonous crops - some of which have been cultivated for centuries - from the more resistant GM sorts and possible subsequent extinction of several animal species. Hungarian Greenpeace activists - who had poured several sacks of maize on the street in front of the Agriculture Ministry's entrance shortly before the decision - welcomed the ban as long overdue. While they also claimed that the ban is the only way to protect farmers from damages from the cultivation of GM plants, they admitted that prohibition of foods derived from GM plants was not possible since no scientific evidence has so far proven harmful health effects.

HungaryHungary

05.03.2012

It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...

HungaryHungary

09.08.2011

Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...

HungaryHungary

09.08.2011

Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...

HungaryHungary

04.04.2011

Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...

HungaryHungary

06.02.2011

Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term...

HungaryHungary

03.11.2010

Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...

HungaryHungary

16.09.2010

Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically...

HungaryHungary

01.07.2010

Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...

HungaryHungary

01.02.2010

Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-hungary/article/mon810-gm-maize-banned.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • MERCK KGAA72.63 EUR4.35%
  • MAGFORCE7.30 EUR4.29%

FLOP

  • CYTOS0.21 CHF-8.70%
  • WILEX2.22 EUR-5.93%
  • CO.DON3.08 EUR-5.81%

TOP

  • PAION3.25 EUR31.0%
  • CO.DON3.08 EUR23.2%
  • EPIGENOMICS3.80 EUR22.6%

FLOP

  • CYTOS0.21 CHF-19.2%
  • ADDEX3.25 CHF-18.8%
  • MEDIGENE3.86 EUR-17.0%

TOP

  • SANTHERA89.30 CHF2088.7%
  • CO.DON3.08 EUR234.8%
  • PAION3.25 EUR221.8%

FLOP

  • CYTOS0.21 CHF-94.8%
  • BIOFRONTERA2.24 EUR-38.6%
  • 4SC1.14 EUR-38.4%

No liability assumed, Date: 22.09.2014


Current issue

All issues

Product of the week

Products